Prognostic value of inflammation-based indexes for intrahepatic cholangiocarcinoma following curative resection.
inflammation
intrahepatic cholangiocellular carcinoma
lymphocyte to macrophage ratio
neutrophil to lymphocyte ratio
prognostic factors
Journal
Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
received:
28
01
2018
accepted:
06
09
2018
entrez:
19
1
2019
pubmed:
19
1
2019
medline:
19
1
2019
Statut:
ppublish
Résumé
It is widely acknowledged that inflammatory indices may serve as effective prognosis indicators for various malignancies. In the present study, the prognostic value of systemic inflammatory biomarkers for patients undergoing curative resection for intrahepatic cholangiocellular carcinoma (ICC) was investigated. Clinical data of ICC patients who underwent curative resection between September 2008 and July 2017 were collected. Inflammatory indictors were analyzed using the Area Under the Receiver Operating Characteristic Curve. Indictors that were significantly associated with the overall survival (OS) were used to establish a systemic inflammation-based score system and tested via nomogram using R software. The neutrophil To lymphocyte ratio (NLR) and lymphocyte to macrophages ratio (LMR) were significantly associated with the OS and disease-free survival of the patients. High NLR and low LMR were associated with worse clinicopathological and survival outcomes. The univariate and multivariate analyses indicated that tumor T stage, incisal margin, NLR and LMR were associated with the OS of the patients. The systemic inflammation-based scoring system based on LMR and NLR demonstrated a stronger discriminatory capacity and may serve as a useful prognostic parameter for patients undergoing curative resection for ICC. Low LMR and high NLR were observed to be associated with poor prognosis and worse clinical outcomes for patients with ICC undergoing curative surgery. A combined inflammation-based scoring system based on LMR and NLR may effectively predict the outcomes and serve as a novel prognostic predictor for these patients.
Identifiants
pubmed: 30655752
doi: 10.3892/ol.2018.9618
pii: OL-0-0-9618
pmc: PMC6313216
doi:
Types de publication
Journal Article
Langues
eng
Pagination
165-174Références
Oncogene. 2006 Mar 30;25(14):2105-12
pubmed: 16288213
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
Dig Dis Sci. 2010 Dec;55(12):3597-601
pubmed: 20848202
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Can J Gastroenterol. 2011 Nov;25(11):603-8
pubmed: 22059167
J Clin Oncol. 2013 Mar 20;31(9):1188-95
pubmed: 23358969
JAMA Surg. 2014 May;149(5):432-8
pubmed: 24599477
World J Gastroenterol. 2014 Sep 7;20(33):11630-40
pubmed: 25206269
Leuk Lymphoma. 2016;57(1):58-62
pubmed: 25926063
J Gastroenterol. 2016 Feb;51(2):153-61
pubmed: 26187429
J Am Coll Surg. 2015 Aug;221(2):452-61
pubmed: 26206643
World J Gastrointest Oncol. 2015 Aug 15;7(8):111-7
pubmed: 26306143
J Clin Invest. 2015 Sep;125(9):3347-55
pubmed: 26325032
Int J Cancer. 2016 Jul 1;139(1):220-31
pubmed: 26933932
J Surg Oncol. 2016 Aug;114(2):202-10
pubmed: 27199001
Cell Biochem Biophys. 2015 Nov;73(2):455-460
pubmed: 27352338
Onco Targets Ther. 2016 Oct 19;9:6417-6423
pubmed: 27799789
Oncotarget. 2016 Dec 6;7(49):81830-81838
pubmed: 27833084
Oncotarget. 2017 Mar 21;8(12):18792-18801
pubmed: 27852046
World J Surg Oncol. 2016 Nov 16;14(1):289
pubmed: 27852294
Oncotarget. 2017 Jan 17;8(3):4301-4312
pubmed: 27935864
Oncotarget. 2017 Jan 17;8(3):5219-5232
pubmed: 28029650
Oncotarget. 2017 Feb 21;8(8):13293-13303
pubmed: 28076328
Clin Lab. 2016 Aug 1;62(8):1443-1449
pubmed: 28164624
HPB (Oxford). 2017 May;19(5):458-464
pubmed: 28190710
Oncotarget. 2017 May 30;8(22):36161-36170
pubmed: 28212535
PLoS One. 2017 Feb 23;12(2):e0170605
pubmed: 28231294
Onco Targets Ther. 2017 Mar 06;10:1441-1449
pubmed: 28331337
PLoS One. 2017 Mar 29;12(3):e0174769
pubmed: 28355305
Asian J Surg. 2018 Jul;41(4):341-348
pubmed: 28365200
Sci Rep. 2017 Apr 18;7:46601
pubmed: 28417972
Oncotarget. 2017 Jul 11;8(28):45178-45189
pubmed: 28423351
Rep Pract Oncol Radiother. 2017 Mar-Apr;22(2):176-180
pubmed: 28490990
Expert Opin Emerg Drugs. 2017 Jun;22(2):191-200
pubmed: 28506080
World J Gastroenterol. 2017 May 7;23(17):3122-3132
pubmed: 28533669
Mol Cell Biochem. 2018 Jan;437(1-2):13-36
pubmed: 28593566
Hepatobiliary Pancreat Dis Int. 2017 Jun;16(3):264-270
pubmed: 28603094
Ann Hepatol. 2017 Aug 1;16(4):565-568
pubmed: 28611259
Expert Rev Gastroenterol Hepatol. 2017 Aug;11(8):759-772
pubmed: 28613087
J Clin Gastroenterol. 2018 Mar;52(3):262-267
pubmed: 28617762
Ann Glob Health. 2017 Mar - Apr;83(2):281-292
pubmed: 28619403
BMC Cancer. 2017 Jul 3;17(1):464
pubmed: 28673346
J Hepatocell Carcinoma. 2017 Jun 23;4:81-92
pubmed: 28721349
Medicine (Baltimore). 2017 Aug;96(34):e7891
pubmed: 28834905
Oncotarget. 2017 Jun 19;8(40):68837-68846
pubmed: 28978160
Oncotarget. 2017 Jun 13;8(43):75627-75637
pubmed: 29088897
Oncotarget. 2017 May 24;8(45):79366-79375
pubmed: 29108315